Αρχική World News Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced... World News Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations Από Ogkologos - 30 Ιουνίου, 2025 888 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... 17 Αυγούστου, 2020 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... 28 Σεπτεμβρίου, 2023 Can Cancer Prevention Be Better Integrated into Primary Care? 5 Ιουνίου, 2023 Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... 26 Μαρτίου, 2025 Φόρτωση περισσοτέρων HOT NEWS 15% of People With Lung Cancer Have an Inherited Mutation for... Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... For People with Cancer, Are Steroids the Best Treatment for Breathing...